...Euronext:SAN; NASDAQ:SNY). Mu is a veteran of Simcere Pharmaceutical Group Ltd....
...president of R&D and later president of Simcere’s...

...Commission.Over 85% of NHSA’s disease categories were covered by added drugs, including Sanbexin edaravone/dexborneol from Simcere Pharmaceutical Group Ltd....

...from urge urinary incontinence, urgency and urinary frequency.NMPA reviewing subcutaneous PD-L1 inhibitorAlphamab Oncology Ltd. and Simcere Pharmaceutical Group Ltd....
...deficient (dMMR) solid tumors. If approved, envafolimab could become the first subcutaneous anti-PD-1/PD-L1 antibody globally. Simcere...

...as a drug developer includes tenures at Simcere Pharmaceutical Group Ltd....
...president of R&D and later president of Simcere’s...

...CMO Hua Mu, is a veteran of Simcere Pharmaceutical Group Ltd....
...president of R&D and later president of Simcere’s...

...reimbursements. It’s also eligible for $915 million in milestones.Simcere slips in Hong Kong debutShares of Simcere Pharmaceutical Group Ltd....
...The deal came at a valuation of about $4.6 billion. Once primarily a generics company, Simcere...

...Ventures and Octopus Ventures. Existing investors Amadeus Capital Partners, Delin Ventures and Kindred Capital also participated.Simcere...
...the midpoint, the company would raise HK$3.4 billion (US$433.7 million) and be valued HK$33.6 billion. Simcere...
...SGI-110, s110) Makena (gestiva, hydroxyprogesterone caproate injection, 17P) Regeneron Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. Otsuka Pharmaceutical Factory Inc. Ori Biotech Ltd. Simcere Pharmaceutical Group Ltd. AMAG...

...a valuation of $91.7 million. Wednesday also saw a new addition to the IPO queue. Simcere Pharmaceutical Group Ltd....
...CROs and CMOs. Elizabeth S. Eaton, Staff Writer Avidity Biosciences Inc. Generation Bio Co. Lantern Pharma Inc. Burning Rock Biotech Ltd. Simcere Pharmaceutical Group Ltd. Vaxcyte...

...and the S&P Biotech ETF (XBI) fell 6%. Simcere lines up for Hong Kong IPO Simcere Pharmaceutical Group Ltd....
...company’s oncology, neurology and autoimmune pipeline includes 50 candidates ranging from preclinical to late-stage development. Simcere...
...undisclosed investment in the firm’s second therapeutics-focused fund. BioCentury Staff Lantern Pharma Inc. Cue Health Inc. Pureos Bioventures Sanofi Cathay Capital 4BIO Capital Simcere Pharmaceutical Group Ltd. IPO...

...an R&D center in Beijing in 2011 and formed a JV the same year with Simcere...